Hosted on MSN10h
Gilead Sciences, Inc. (GILD) is Attracting Investor Attention: Here is What You Should KnowGilead Sciences (GILD) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term. Over ...
TD Cowen analyst Tyler Van Buren maintained a Buy rating on Gilead Sciences (GILD – Research Report) today and set a price target of ...
Zacks.com on MSN10h
Brokers Suggest Investing in Gilead (GILD): Read This Before Placing a BetWhen deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often ...
Citi initiates coverage of Gilead Sciences and Vertex Pharmaceuticals at buy in the large U.S. biotech sector. Read more here.
(RTTNews) - Gilead Sciences Inc. (GILD) announced the pricing of senior unsecured notes in an aggregate principal amount of $3.5 billion, in an underwritten, registered public offering, consisting of ...
Gilead (GILD) reported positive results from a pivotal Phase 3 study of its twice-yearly HIV prevention treatment lenacapavir ...
Gilead stock surges after Q3 earnings beat estimates and raised FY 2024 guidance, with strong HIV drug sales and analyst ...
Gilead Sciences (GILD) reported $7.55 billion in revenue for the quarter ended September 2024, representing a year-over-year increase of 7%. EPS of $2.02 for the same period compares to $2.29 a ...
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
On Tuesday, Gilead Sciences, Inc. (GILD) stock saw a modest uptick, ending the day at $90.22 which represents a slight increase of $0.38 or 0.42% from the prior close of $89.84. The stock opened at ...
Below is Validea's guru fundamental report for GILEAD SCIENCES, INC. (GILD). Of the 22 guru strategies we follow, GILD rates highest using our Earnings Yield Investor model based on the published ...
FOSTER CITY, Calif., November 14, 2024--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD), a biopharmaceutical company ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback